Literature DB >> 29551551

Correlates of specialty substance use treatment among adults with opioid use disorders.

Eric Romo1, Christine M Ulbricht2, Robin E Clark3, Kate L Lapane4.   

Abstract

AIMS: To identify factors associated with the receipt of specialty substance use treatment among adults with opioid use disorders (OUD).
DESIGN: Cross-sectional study based on 2010-2014 National Surveys on Drug Use and Health (NSDUH). SETTING AND PARTICIPANTS: Adults with a past-year OUD (n = 2488). The sample is representative of non-institutionalized US adults. MEASUREMENTS: Past-year OUD was determined using DSM-IV criteria. Past-year specialty substance use treatment was defined as receiving treatment for drug use at any of the following locations: rehabilitation facilities, hospitals (inpatient only), outpatient mental health centers, private doctors' offices, or methadone clinics. Multivariable logistic regression models were used to measure the independent association between potential correlates and specialty substance use treatment receipt.
FINDINGS: Of adults with an OUD, 8.3% received past-year specialty substance use treatment. In a fully adjusted logistic regression model, the following factors were associated with increased odds of receiving specialty substance use treatment: ≥ 35 years old (adjusted Odds Ratio (aOR) = 2.55, 95% Confidence Interval (CI) = 1.04-6.26); unemployment (aOR = 1.92, 95% CI = 1.02-3.61); not in the labor force (aOR = 2.16, 95% CI = 1.15-4.06); never been married (aOR = 2.14, 95% CI = 1.04-4.39); arrested in past 12 months (aOR = 4.43, 95% CI = 2.45-7.99); opioid dependence (aOR = 3.82, 95% CI = 2.06-7.10); alcohol use disorder (aOR = 2.44, 95% CI = 1.44-4.11); and another drug use disorder (aOR = 3.22, 95% CI = 1.95-5.32). Living in a non-metropolitan county (aOR = 0.29, 95% CI = 0.12-0.68) and fair/poor health (aOR = 0.38, 95% CI = 0.17-0.86) were associated with decreased odds of receiving specialty substance use treatment.
CONCLUSIONS: These findings suggest a need for the following efforts: strategies to increase individuals' recognition of their need for OUD treatment, expansion of insurance coverage for substance use treatment, expansion of earlier intervention services, adoption of a chronic care approach to substance use treatment, and an expansion of treatment capacity for rural communities.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Heroin; Opioid use disorders; Prescription opioids; Specialty substance use treatment; Substance use treatment

Mesh:

Year:  2018        PMID: 29551551     DOI: 10.1016/j.addbeh.2018.03.012

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  5 in total

1.  Comparing Buprenorphine-Prescribing Physicians Across Nonmetropolitan and Metropolitan Areas in the United States.

Authors:  Lewei Allison Lin; Hannah K Knudsen
Journal:  Ann Fam Med       Date:  2019-05       Impact factor: 5.166

2.  Impact of health reform on health insurance status among persons who use opioids in eastern Kentucky: A prospective cohort analysis.

Authors:  Hannah K Knudsen; Michelle R Lofwall; Sharon L Walsh; Jennifer R Havens
Journal:  Int J Drug Policy       Date:  2019-05-01

3.  Geographic access to buprenorphine prescribers for patients who use public transit.

Authors:  C Drake; J M Donohue; D Nagy; C Mair; K L Kraemer; D J Wallace
Journal:  J Subst Abuse Treat       Date:  2020-08-05

4.  Inpatient Opioid Use Disorder and Social Determinants of Health: A Nationwide Analysis of the National Inpatient Sample (2012-2014 and 2016-2017).

Authors:  Saanie Sulley; Memory Ndanga
Journal:  Cureus       Date:  2020-11-03

5.  "It's way more than just writing a prescription": A qualitative study of preferences for integrated versus non-integrated treatment models among individuals with opioid use disorder.

Authors:  Elizabeth C Saunders; Sarah K Moore; Olivia Walsh; Stephen A Metcalf; Alan J Budney; Patricia Cavazos-Rehg; Emily Scherer; Lisa A Marsch
Journal:  Addict Sci Clin Pract       Date:  2021-01-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.